Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
Ulrich Gatzemeier, G. Groth, Charles Andrew Butts et al. · Annals of Oncology · 2003
Cited by 388 works. doi:10.1093/annonc/mdh031 Open-access PDF
Authors
- Ulrich Gatzemeier
- G. Groth
- Charles Andrew Butts
- Nico van Zandwijk
- Frances A. Shepherd
- Andrea Ardizzoni
- Claire M. Barton
- Parviz Ghahramani
- Vera Hirsh
References
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- 1969 Cancer Facts and Figures
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
- Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
- Doxorubicin-Induced Cardiomyopathy
- Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer